News

The subpoenas relate to investigations into the sales and marketing of Risperdal by Janssen, Topamax by Ortho-McNeil and Natrecor by Scios – each subsidiaries of Johnson & Johnson.

The drug’s indication is treatment of growth failure in children with growth hormone deficiency and short stature associated with Turner Syndrome. The FDA requested additional support data regarding

Schering-Plough said that the acquisition would fill a gap in the company's late-stage pipeline by adding five compounds in phase III development and a number of promising projects

Subject to completion, which Japan-based Takeda expects to occur within a few weeks, Paradigm will become a subsidiary of Takeda Europe Holdings, a wholly owned subsidiary of Takeda.

Johnson & Johnson will also have to update the safety information on its erythropoiesis-stimulating agent (ESA) drug Procrit. ESAs are approved to treat anemia in patients with chronic

Patients receiving daclizumab 2mg/kg subcutaneously every two weeks showed a significant reduction in the number of new or enlarged gadolinium-contrast-enhancing lesions (Gd-CELs) at week 24. Daclizumab is a

The FDA published the notice on its website, urging physicians to consider the risk of fracture when treating female patients with type 2 diabetes with pioglitazone-containing products. Three

Teva said that the agency had approved its abbreviated new drug application for moexipril HCl and hydrochlorothiazide tablets, in 7.5mg/12.5mg, 15mg/12.5 mg and 15mg/25mg strengths. The company said

This vaccine is designed to prevent infection by human papillomavirus types 6, 11, 16, 18, 31, 45, and 58, which is expected to provide broader protection than the